RxDoctor Payments Data

Ioleen Dell, MD

Internal Medicine · Gainesville, FLNPI 1588777692

Payments from drug & device makers

$12,028in general payments, 2019–2025

Across 522 payments — averaging $23.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Amgen$1K
  • Lilly USA, LLC$1K
  • Boehringer Ingelheim$1K
  • AstraZeneca$974
  • AbbVie$622
  • plus $5K from 34 others

What the payments were for

  • Food & beverage$11,994100%
  • Education$340%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,028 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$371,424
Medicare patients
375
Services billed
12,106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin70$67,384
OzempicSemaglutide58$51,434
EliquisApixaban37$42,421
FarxigaDapagliflozin Propanediol33$30,925
JanuviaSitagliptin Phosphate32$29,361
Xtampza ErOxycodone Myristate24$14,472
RybelsusSemaglutide13$13,272
Spiriva HandihalerTiotropium Bromide15$12,979
BelbucaBuprenorphine Hcl12$10,032
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$8,115
MyrbetriqMirabegron14$7,940
Tresiba Flextouch U-200Insulin Degludec19$7,750
Valsartan186$4,229
Atorvastatin Calcium384$3,460
Rosuvastatin Calcium297$3,420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$1,042$67,38470 claims
Novo NordiskOzempic, Rybelsus$1,905$64,70671 claims
PfizerEliquis$600$42,42137 claims
AstraZenecaFarxiga$974$30,92533 claims
MerckJanuvia$227$29,36132 claims
Astellas Pharma US IncMyrbetriq$217$7,94014 claims
AbbVieSynthroid$622$2,85840 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Gainesville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →